A Rational Approach to a De-Escalation of Double Antithrombotic Therapy: The Possibilities of Clopidogrel

In the review based on existing clinical recommendations and guidelines of the European cardiology society and results of clinical and register trials difficult questions about a antithrombotic therapy in the patients with an acute coronary syndrome and percutaneous coronary interventions were discussed. The perspective strategy of risk management on ischemic and hemorrhagic events were described. Need of the maximum personification of purpose of double antithrombotic therapy at patients with an acute coronary syndrome or after carrying out transdermal coronary interventions is updated. Real requirement on constant assessment of balance in risks of ischemic and hemorrhagic events in this group of patients were defined. The perspective strategy of risk management in ischemic and hemorrhagic events from a position of results of relevant clinical trials were described. Results of clinical trials (TOPIC, TROPICAL-ACS) about transfer the ACS patients from “new” desaggregants on clopidogrel were presented (De-Escalation approach). Examples of the clinical situations suitable for realization of such approach were reviewed. The prospects of use of De-Escalation approach are designated and positions of a clopidogrel and, in particular, the original drug Plavix were provided. At the same time, appointment in patients with ACS within 12 months of double antiaggregant therapy is the proved option of treatment allowing to improve the prognisis. However, in some cases there is a reasonable requirement of the transfer of the patient from the “new” antiaggregants (ticagrelor or prasugrel) to clopidogrel (“de-escalation”). It needs to perfome according to the available evidence base recommendations and it is strict according to clinical indications. In particular, patients can have a perspective de-escalation with high risk of bleedings or with already developed bleeding; in patients with the forced refusal of reception of “new” antiaggregants owing to development of side effects / intolerance / allergic reactions; in the presence of indications for life long intake of anticoagulants in case of the need for purpose of double or triple antithrombotic therapy; in patients with ACS with low risk.

acute coronary syndrome, antithrombotic therapy, antiaggregants, de-escalation, clopidogrel

1. Kashtalap V.V., Barbarash O.L. Actual problems of antithrombotic therapy in acute coronary syndrome (following the material presented at the European society of cardiology congress 2017). Medicinskiy sovet = Medical Council. 2017;(12):82-88. (In Russ.). doi: 10.21518/2079- 701X-2017-12-82-88.

2. Healthcare in Russia. 2017: statistical collection. (In Russ.). Available at: http://www.gks.ru/bgd/ regl/b17_34/Main.htm.

3. Oganov R.G., Kontsevaya A.V., Kalinina A.M. Economic burden of cardiovascular disease in the Russian Federation. Cardiovascular Therapy and Prevention. 2011;(4):4-9 (In Russ.) Available at: https://cardiovascular.elpub.ru/jour/article/view/1876.

4. Marcucci R., Patti G., Calabrò P., Gori A.M., Grossi G., Cirillo P., Pengo V., Gresele P., Pignatelli P., Antonucci E., di Mario C., Valente S., Palareti G.Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry. PLoS One. 2019;14(7):e0219676. doi: 10.1371/journal. pone.0219676.

5. Smolina K., Wright F.L., Rayner M., Goldacre M.G. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovascular Qual Outcomes. 2012;5:532-540. doi: 10.1161/ CIRCOUTCOMES.111.964700.

6. Valgimigli M., Bueno H., Byrne R.A., Collet J.P., Costa F., Jeppsson A., Jüni P., Kastrati A., Kolh P., Mauri L., Montalescot G., Neumann F.J., Petricevic M., Roffi M., Steg P.G., Windecker S., Zamorano J.L., Levine G.N.; 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213-260. doi: 10.1093/eurheartj/ehx419.

7. Ehrlich A.D., Barbarash O.L., Kashtalap V.V., Gratsiansky N.A. on behalf of all participants of the RECORD-3 registry. Compliance with clinical practice guidelines for non ST-segment elevation acute coronary syndrome: association between outcomes and predictors of poor management (RECORD-3 Registry data). Kompleksnye problemy serdechno-sosudistykh zabolevaniy = Complex issues of cardiovascular diseases. 2016;(2): 75-82. (In Russ.) doi: 10.17802/2306-1278-2016-2-75-82.

8. Morrow D.A., Wiviott S.D., White H.D., Nicolau J.C., Bramucci E., Murphy S.A., Bonaca M.P., Ruff C.T., Scirica B.M., McCabe C.H., Antman E.M., Braunwald E. Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel– Thrombolysis in Myocardial Infarction 38. An Application of the Classification System From the Universal Definition of Myocardial Infarction. Circulation. 2009;119:2758-2764. doi: 10.1161/CIRCULATIONAHA.108.833665.

9. Steg P.G., James S., Harrington R.A., Ardissino D., Becker R.C., Cannon C.P., Emanuelsson H., Finkelstein A., Husted S., Katus H., Kilhamn J., Olofsson S., Storey R.F., Weaver W.D., Wallentin L.; for the PLATO Study Group. Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention. A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis. Circulation. 2010;122:2131- 2141. doi: 10.1161/ CIRCULATIONAHA.109.927582.

10. Erlikh A.D., Gratsiansky N.A. On Behalf Of Record-Participants. Registry of Acute Coronary Syndromes RECORD-3. Characteristics of Patients and Treatment During Initial Hospitalization. Kardiologiia. 2016;56(4):16-24. (In Russ.) doi: 10.18565/cardio.2016.4.16-24

11. Sedykh D.Yu., Gorbunova E.V., Zykov M.V., Kashtalap V.V., Barbarash O.L. Factors associated with the risk of death and hospitalization in recurrent myocardial infarction. Kreativnaya kardiologiya = Creative Cardiology. 2017;11(2):98–108. (In Russ.). doi: 10.24022/1997-3187-2017-11-2-98-108.

12. Tolpygina S.N., Polyanskaya Yu.N., Martsevich S.Yu. Treatment of patients with chronic ischemic heart disease in real clinical practice according to the data from PROGNOZ IBS register (part 2). Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2013;9(5):494-499 (In Russ.) Available at: https://elibrary.ru/item. asp?id=21561195.

13. Bonaca M.P., Bhatt D.L., Cohen M., Steg P.G., Storey R.F., Jensen E.C., Magnani G., Bansilal S., Fish M.P., Im K., Bengtsson O., Oude Ophuis T., Budaj A., Theroux P., Ruda M., Hamm C., Goto S., Spinar J., Nicolau J.C., Kiss R.G., Murphy S.A., Wiviott S.D., Held P., Braunwald E., Sabatine M.S.; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–1800. doi: 10.1056/ NEJMoa1500857.

14. Zettler M.E., Peterson E.D., McCoy L.A., Effron M.B., Anstrom K.J., Henry T.D., Baker B.A., Messenger J.C., Cohen D.J., Wang T.Y.; TRANSLATE-ACS Investigators. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. Am Heart J. 2017;183:62-68. doi: 10.1016/j.ahj.2016.10.006.

15. Neumann F.J., Sousa-Uva M., Ahlsson A., Alfonso F., Banning A.P., Benedetto U., Byrne R.A., Collet J.P., Falk V., Head S.J., Jüni P., Kastrati A., Koller A., Kristensen S.D., Niebauer J., Richter D.J., Seferovic P.M., Sibbing D., Stefanini G.G., Windecker S., Yadav R., Zembala M.O.; 2018 ESC/EACTS Guidelines on myocardial revascularization. ESC Scientific Document Group. Eur Heart J. 2019;40(2):87-165. doi: 10.1093/eurheartj/ehy394.

16. Winter M.P., von Lewinski D., Wallner M., Prüller F., Kolesnik E., Hengstenberg C., Siller-Matula J.M. Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study. Sci Rep. 2019;9(1):8194. doi: 10.1038/s41598-019- 44673-7.

17. Yakovlev A.N. Possibility of replacing one antiaggregant to another. Medicinskiy sovet = Medical Council. 2018;(5):54-56. (In Russ.) doi: 10.21518/2079-701X-2018-5-54-56.

18. Angiolillo D.J., Rollini F., Storey R.F., Bhatt D.L., James S., Schneider D.J., Sibbing D., So D.Y.F, Trenk D., Alexopoulos D., Gurbel P.A., Hochholzer W., De Luca L., Bonello L., Aradi D., Cuisset T., Tantry U.S., Wang T.Y., Valgimigli M., Waksman R., Mehran R., Montalescot G., Franchi F., Price M.J. International Expert Consensus on Switching Platelet P2Y12 Receptor–Inhibiting Therapies. Circulation. 2017;136:1955-1975. doi: 10.1161/CIRCULATIONAHA.117.031164.

19. Cuisset T., Deharo P., Quilici J., Johnson T.W., Deffarges S., Bassez C., Bonnet G., Fourcade L., Mouret J.P., Lambert M., Verdier V., Morange P.E., Alessi M.C., Bonnet J.L. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timingof platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38(41):3070- 3078. doi: 10.1093/eurheartj/ehx175.

20. Deharo P., Quilici J., Camoin-Jau L., Johnson T.W., Bassez C., Bonnet G., Fernandez M., Ibrahim M., Suchon P., Verdier V., Fourcade L., Morange P.E., Bonnet J.L., Alessi M.C., Cuisset T. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity The TOPICVASP Pre-Specified Analysis of the TOPIC Randomized Study. JACC: Cardiovascular Interventions. 2017;10(24):2560–2570. doi: 10.1016/j.jcin.2017.08.044.

21. Sibbing D., Aradi D., Jacobshagen C., Gross L., Trenk D., Geisler T., Orban M., Hadamitzky M., Merkely B., Kiss R.G., Komócsi A., Dézsi C.A., Holdt L., Felix S.B., Parma R., Klopotowski M., Schwinger R.H.G., Rieber J., Huber K., Neumann F.J., Koltowski L., Mehilli J., Huczek Z., Massberg S.; TROPICAL-ACS Investigators. Guided deescalation of antiplatelet treatment in patients with acute coronary syndromeundergoing percutaneous coronary intervention (TROPICALACS): a randomised, open-label, multicentre trial. Lancet. 2017;390(10104):1747-1757. doi: 10.1016/S0140-6736(17)32155-4.

22. Shapiro C.L. De-escalation yes, but not at the expense of efficacy: in defense of better treatment. NPJ Breast Cancer. 2019;5:25. doi: 10.1038/s41523-019-0120-z.

23. Lake D., Seidman A.D. Adjuvant chemotherapy for node negative, high Recurrence ScoreTM breast cancer: in defense of de-escalation. NPJ Breast Cancer. 2019 Aug 12;5:24. doi: 10.1038/ s41523-019-0119-5.

24. Israel A., Jurdi K.E., Rubin D.T. Treatment De-Escalation in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2019;15(6):335-341. Available at: https://www. ncbi.nlm.nih.gov/pubmed/31391803.

25. Jermendy G. De-escalation of antihyperglycemic treatment in patients with type 2 diabetes - when less is more. Orv Hetil. 2019;160(31):1207-1215. doi: 10.1556/650.2019.31488. Hungarian.

26. Wolfe J.R., Bryant A.M., Khoury J.A. Impact of an automated antibiotic time-out alert on the deescalation of broad-spectrum antibiotics at a large community teaching hospital. Infect Control Hosp Epidemiol. 2019 Aug 22:1-3. doi: 10.1017/ice.2019.197.

27. Petteys M.M., Kachur E., Pillinger K.E., He J., Copelan E.A., Shahid Z. Antimicrobial de-escalation in adult hematopoietic cell transplantation recipients with febrile neutropenia of unknown origin. J Oncol Pharm Pract. 2019 Aug 18:1078155219865303. doi: 10.1177/1078155219865303.

28. Bultas A.C., Bery A.I., Deal E.N., Hartmann A.P., Richter S.K., Call W.B. Predictors of Treatment Failure Following De-escalation to a Fluoroquinolone in Culture-Negative Nosocomial Pneumonia. Ann Pharmacother. 2019 Jul 26:1060028019867114. doi: 10.1177/1060028019867114.

29. Byoung Soo K., Sang Ho C., Younsuck K., JinWon H., Sang-Bum H., Chae-Man L. Safety of antimicrobial de-escalation for culture-negative severe pneumonia. J Crit Care. 2019;54:14- 19. doi: 10.1016/j.jcrc.2019.06.026.

30. Cavallari L.H., Lee C.R. A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary angioplasty. Future Cardiol. 2019;15(4):251-254. doi: 10.2217/fca-2019-0017.